Tirzepatide improves kidney outcomes in T2DM with increased CV risk
Babies exposed to COVID in the womb show neurodevelopmental changes
6 June 2022Skin biopsy? Here are tips on wound care
6 June 2022Tirzepatide improves kidney outcomes in T2DM with increased CV risk
An exploratory analysis of data from the SURPASS-4 trial has shown that adults with type 2 diabetes and increased cardiovascular risk receiving tirzepatide experience fewer renal complications, especially new onset of macroalbuminuria; these findings were presented at the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
